Expansion of the position, dip used. The earnings from corona tests have not even been fully taken into account... I am very optimistic in the long term 👍
Buy. The laboratory and testing specialist, which has only been included in Paris' leading index, the CAC40, since September, met expectations with its figures, but probably disappointed with its outlook. Nevertheless, growth is phenomenal and the P/E ratio for growth (30.9% in the first three months) is attractively low. Even without corona tests, there is a lot of fantasy here... only the dividend yield (0.7%) could be more attractive.
It's always amazing to see which transactions are "invented" by the system here... in the linked securities account, where unfortunately you can hardly exert any influence 🤷♂️ There is and was no sale of this security!
